文献库搜索 | GeneLibs

Henuzet(E),Boon(L),Dumitriu(D),Peetermans(... Cureus 2025-07-00

...PIK3CA)-related overgrowth spectrum (PROS), supporting improved diagnosis and counseling during pregnancy.

Kubota(A),Bandoh(N),Goto(T),Kono(M),Sato(R... Mol Clin Oncol 2025-10-00

...PIK3CA in 2 (8%) of these 24 patients. Multivariate Cox proportional hazard analysis revealed that PIK3CA mutation was a...

Shen(M),Hao(Y),Han(X),Wang(B),Li(L),Chen(T... J Immunother Cancer 2025-07-18

...PIK3CA mutations, which are shared across various tumor types, have demonstrated significant immunogenicity and offer gr...

Khalifa(M),Hmed(AA),Elfeky(KS),Bakry(S),Ha... J Genet Eng Biotechnol 2025-09-00

...PIK3CA. The present study represents the first comprehensive somatic mutation profile in HCC Egyptian patients. This fin...

Ichikawa(R),Sudo(T),Takada(K),Ohwaki(A),It... Fujita Med J 2025-11-00

...PIK3CA, PTEN, PIK3R1, and PIK3R2 were commonly detected. In the χ2 test analysis, TP53 loss (p=0.029), PIK3CA amplificat...

Huang(CC),Yeh(YC),Tsai(YF),Lin(YS),Chao(TC... Biomed Rep 2025-10-00

...PIK3CA and PTEN), which can be acted upon or have clinical relevance for therapeutic intervention and TP53. The concorda...

Putro(YAP),Rifardi(D),Dwianingsih(EK),Prib... Int J Surg Case Rep 2025-09-00

...PIK3CA gene. MDL lacks established diagnostic criteria and management guidelines, with treatment strategies ranging from...

De Angelis(MT),Rizzuto(A),Amaddeo(A),Sagne... J Transl Med 2025-08-06

...PIK3CA, BRAF, and DNAH1 mutations, while RC showed enrichment for TP53 and NRAS mutations. Importantly, analysis of pred...

López-Miranda(E),Pérez-García(JM),Gión(M),... Breast Cancer Res 2025-08-06

...PIK3CA mutational status. Ipatasertib combined with capecitabine or eribulin showed acceptable safety but was not tolera...

Corso(G),Shen(S),Criscitiello(C),Mukhtar(R... Cancer Treat Rev 2025-11-00

...PIK3CA, ERBB2 mutations) and its relationship with endocrine sensitivity and limited immune infiltration. Diagnostic cha...